The pharmaceutical company Incyte has agreed to pay $12.6 million to settle claims under  investigation by the federal government that it created a kickback scheme to increase prescriptions for an expensive blood cancer drug.

The settlement resolves a whistleblower case filed in the Eastern District of Pennsylvania and against the Wilmington, Delaware-headquartered company, accused of donating to a foundation and using those funds toward the copays of Medicare and TRICARE beneficiaries who weren’t eligible for coverage of Incyte Corp.’s drug, Jakafi.